Key Points
- Major shareholder Charles Jobson bought 127,676 shares of The Joint Corp. (NASDAQ:JYNT) at an average price of $8.57, increasing his stake by 7.76% to 1,773,479 shares.
- The Joint reported better-than-expected quarterly results, with earnings of $0.08 per share versus the $0.03 consensus and revenue of $14.82 million versus estimates of $14.50 million.
- Analyst sentiment is mixed but slightly constructive: the stock has a consensus rating of Hold with a $18.00 price target, while recent notes included upgrades from Wall Street Zen and Zacks Research.
The Joint Corp. (NASDAQ:JYNT - Get Free Report) major shareholder Charles Jobson bought 127,676 shares of the stock in a transaction on Tuesday, May 12th. The stock was purchased at an average cost of $8.57 per share, for a total transaction of $1,094,183.32. Following the acquisition, the insider directly owned 1,773,479 shares of the company's stock, valued at $15,198,715.03. The trade was a 7.76% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Joint Stock Performance
Joint stock opened at $8.21 on Friday. The firm has a market capitalization of $117.07 million, a price-to-earnings ratio of 35.70 and a beta of 1.11. The Joint Corp. has a fifty-two week low of $7.50 and a fifty-two week high of $13.47. The stock's fifty day moving average is $8.67 and its two-hundred day moving average is $8.82.
Joint (NASDAQ:JYNT - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.05. The company had revenue of $14.82 million for the quarter, compared to analyst estimates of $14.50 million. Joint had a return on equity of 7.00% and a net margin of 5.72%. As a group, sell-side analysts forecast that The Joint Corp. will post 0.51 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the company. Wall Street Zen raised Joint from a "hold" rating to a "buy" rating in a report on Saturday, May 9th. Zacks Research raised Joint from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Finally, Weiss Ratings lowered Joint from a "sell (d+)" rating to a "sell (d)" rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Joint currently has an average rating of "Hold" and a consensus price target of $18.00.
Read Our Latest Analysis on JYNT
Institutional Trading of Joint
A number of large investors have recently made changes to their positions in JYNT. BNP Paribas Financial Markets boosted its stake in shares of Joint by 104.7% during the third quarter. BNP Paribas Financial Markets now owns 2,935 shares of the company's stock valued at $28,000 after acquiring an additional 1,501 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Joint by 32.3% during the second quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company's stock valued at $86,000 after acquiring an additional 1,810 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Joint by 25.9% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company's stock valued at $95,000 after acquiring an additional 1,698 shares during the last quarter. Stoneridge Investment Partners LLC acquired a new stake in shares of Joint during the third quarter valued at $117,000. Finally, XTX Topco Ltd acquired a new stake in shares of Joint during the fourth quarter valued at $124,000. Institutional investors and hedge funds own 76.88% of the company's stock.
Joint Company Profile
(
Get Free Report)
The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.
Joint's growth strategy centers on partnering with franchisees to expand its network of clinics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
